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Current consensus about treatment of HIV infection is
that HAART must include two nucleoside reverse tran-
scriptase inhibitors plus a third drug (one non-nucleo-
side reverse transcriptase inhibitor, a boosted protease
inhibitor, an integrase strand transfer inhibitor and pos-
sibly a CCR5 inhibitor). There is a lot of interest about
changing the basic structure of the antiretroviral regi-
men so we can be able to use nucleoside-sparing regi-
mens. The main reason to support the investigation of
NRTI-sparing strategies is the concern about the long-
term toxicity of tenofovir and abacavir.
In antiretroviral naïve patients candidates for nucleo-
side sparing regimens have included a boosted or
unboosted protease inhibitor as the backbone drug to
which a non-nucleoside reverse transcriptase inhibitor,
an integrase inhibitor, a single nucleoside or a CCR5
inhibitor has been added. In patients who have already
achieved suppression it is possible that a boosted pro-
tease inhibitor used as monotherapy might be all what
is needed to maintain suppression. It is reasonable to
predict that, compared to triple-drug HAART, the long
term toxicity of these single and dual-drug regimens
would be lower. Finding the right number of antiretro-
virals that offers the optimal balance of long-term effi-
cacy and toxicity is therefore a very important scientific
question.
This presentation would review the clinical trials that
have explored NRTI sparing strategies for the treatment
of antiretroviral naïve patients and also for maintenance
of viral suppression. The presentation would highlight
the possible benefits associated to NRTI-sparing strate-
gies and the most promising candidates.
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